Mergers & acquisitions
Platinum Equity submitted a binding offer to Johnson & Johnson to buy LifeScan for $2.1 billion.
Lunbeck is acquiring Prexton Therapeutics BV, a 2012 spinout from Merck KgaA, and its Phase II treatment for Parkinson’s disease.
The Wall Street Journal speculated today that it won’t be long before drug manufacturers start consolidating in order to improve their bottom lines.
Celgene has a deep pipeline and a $69 billion market cap, but it could consider going private in 2019 via a leveraged buyout.
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
U.S. insurer Cigna is acquiring pharmacy benefits manager Express Scripts for approximately $67 billion.
After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Merck is driving forward in its quest to develop a premier immuno-oncology pipeline by acquiring Australia-based Viralytics Limited and its oncolytic immunotherapy treatments.
Life sciences giant Johnson & Johnson may be shopping around its sterilization products division.
PRESS RELEASES